26
Mon, Jun
28 New Articles

Eyelock Patents Iris Recognition

Medico Legal

EyeLock, a leader of iris-based identity authentication solutions, has been issued U.S. Patent No. 9,613,281, broadly covering the linking of an iris image with a
face image acquired in sequence (during the same transaction) and represents the company’s 45th issued patent.

 

The patent is for a method in which images of the iris and face are tracked in a sequence that validates that both images are from the same, live person. The importance in the process is the real-time tracking that links the iris image to the face image.

One use is where a mobile phone incorporating EyeLock’s patented method would use iris authentication sequentially linked to facial imaging or recognition to provide a high level of assertion that the person conducting the transaction is real and not a machine or a hack.

This is merely one example of how EyeLock has achieved significant technological breakthroughs and solved integration challenges that have historically been a barrier to mass-market adoption of iris authentication technology.

In addition, the Company’s approach provides maximum flexibility by offering designs that have either on-board or host-based processing and illumination.

Algorithm performance capabilities for speed and accuracy have been validated by Novetta, a leader in advanced analytics technology and independent biometric testing, as unmatched in the market.

EyeLock is an acknowledged leader in advanced iris authentication for the Internet of Things (IoT), providing the highest level of security with EyeLock ID™ technology.

Iris authentication is highly secure because no two irises are alike and the iris is the most accurate human identifier other than DNA.

These new imaging technologies that are now available have changed the way retina specialists evaluate patients, revealing structures that previously could not be visualized. Allowing physicians to go where they could not previously go in the detection and treatment of retinal diseases.